

Investigating Anticancer Potency of In Vitro Propagated Endemic *Thymus Cilicicus* Boiss. & Bal. Extract on Human Lung, Breast, and Prostate Cancer Cell Lines

Naeem Abdul Ghafoor (✉ merzanaeem007@gmail.com)

Mugla Sitki Kocman University: Mugla Sitki Kocman Universitesi <https://orcid.org/0000-0002-4200-7679>

Selin Galatali

Mugla Sitki Kocman University: Mugla Sitki Kocman Universitesi

Sevil Yeniocak

Mugla Sitki Kocman University: Mugla Sitki Kocman Universitesi

Ergun Kaya

Mugla Sitki Kocman University: Mugla Sitki Kocman Universitesi

Nurdan Sarac

Mugla Sitki Kocman University: Mugla Sitki Kocman Universitesi

Aysel Ugur

Gazi University: Gazi Universitesi

Research Article

Keywords: Cancer, *Thymus cilicicus*, lung cancer, breast cancer, prostate cancer, anticancer agents, molecular docking

Posted Date: January 18th, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-1206301/v1>

License:   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

1 Investigating anticancer potency of *in vitro* propagated endemic *Thymus* 2 *cilicicus* Boiss. & Bal. extract on human lung, breast, and prostate cancer cell 3 lines

4 Naeem Abdul Ghafoor^{1*}, Selin Galatali¹, Sevil Yeniocak¹, Ergun Kaya¹, Nurdan Sarac^{2*}, Aysel Ugur³

5 ¹Department of Molecular Biology and Genetics, Faculty of Science, Mugla Sitki Kocman University,
6 Mugla, Turkey.

7 ²Department of Biology, Faculty of Science, Mugla Sitki Kocman University, Mugla, Turkey

8 ³Section of Medical Microbiology, Department of Basic Sciences, Faculty of Dentistry, Gazi University,
9 Ankara, Turkey

10

11 *Corresponding authors: merzanaeem007@gmail.com, nsarac@mu.edu.tr

12

13 Abstract

14 Cancer is the leading cause of death in the world, accounting for nearly 10 million deaths in 2020 alone and
15 surpassing all other categories by a large margin. Several different strategies have been and are still being
16 deployed to combat different types of cancers and among the common clinical approaches are the use of
17 synthetic and natural compounds as anticancer agents within chemotherapy regimens. *Thymus cilicicus*
18 Boiss. & Bal is a spice endemic to Turkey, the Northern Aegean Islands, Lebanon, and Syria, while several
19 species of the *Thymus* genus are known to exhibit different clinically valuable properties, the research on
20 *T. cilicicus* is rather scarce, therefore, in this study, the wound healing properties of *in vitro* propagated *T.*
21 *cilicicus* ethanolic extracts were investigated on murine fibroblast (NIH-3T3), and its anticancer potency
22 was investigated on the human alveolar basal epithelial adenocarcinoma (A549), human breast
23 adenocarcinoma (MDA-MB-213), and human prostate cancer (DU-145) cell lines via colorimetric MTT
24 assays. The wound healing property assessments didn't lead to any significant results, however, *T. cilicicus*
25 yielded selective and promising anticancer potency on the A549 cell line. Furthermore, molecular docking
26 analyses were on the proteins of 9 genes confirmed to be upregulated in both 3D and 4D A549 cultures
27 against 48 compounds found in the essential oils of *T. cilicicus* were performed and yielded results
28 acquiescent with previous findings in the scientific literature. This study provides *in vitro* evidence to the
29 selective anticancer activity of *T. cilicicus* extracts on A549 cells enhanced with computational evidence
30 on the molecular mechanism involved in this selective activity. This study serves as a precursor for further
31 *in vivo* and clinical research on the constituents of *T. cilicicus* as potent anticancer agents and their potential
32 use in cancer therapies.

33 **Keywords:** Cancer; *Thymus cilicicus*; lung cancer; breast cancer ; prostate cancer; anticancer agents;
34 molecular docking

35 1. Introduction

36 Cancer is the leading cause of death in the world, accounting for nearly 10 million deaths in 2020
37 alone, surpassing all other categories by a large margin (WHO 2021). While 30-50% of cancer cases could
38 be prevented by avoiding the risk factors and implementing prevention strategies, the remaining cases
39 require some form of clinical assistance. The oldest record for a cancer case has been reported from breast

40 cancer in ancient Egypt around 1500 BC, cancer develops in normal cells as they starts proliferating
41 uncontrollably, i.e. when normal healthy cells grow and proliferate without any limitation or restrictions
42 (Sudhakar 2009). DNA damage resulting in tens of thousands of individual molecular lesions per cell per
43 day constantly occur in healthy cells under their regular metabolic activity or when exposed to certain
44 environmental factors, however, under normal circumstances, DNA repair mechanisms recruit several
45 cellular elements through which it identifies and repairs the damage to the DNA molecule, nevertheless,
46 every once in a while depending on the genetic composition of the cell and the environmental factors it's
47 exposed to, certain damage to specific genes aren't properly rectified and hence result in the formation of
48 tumor cells (Lodish et al. 2008). Five major mechanisms involved in this rectification process are, the base
49 excision repair, nucleotide excision repair, mismatch repair, repair by homologous recombination, and
50 repair by non-homologous end joining, different combinations of these pathways are known to be active
51 during different stages of the cell cycle so as to maintain the integrity of the cell's genome and repair any
52 damage, failure of these molecular mechanisms lead to survival and proliferation of the cells with damaged
53 DNA which reflects as tumors (Chatterjee and Walker 2017).

54 The usage of natural compounds from plants, animals, and microorganisms by humans to treat
55 different medical conditions dates long before recorded history, some paleoanthropological studies done in
56 the Middle East concluded that Neanderthals might have been aware of the medicinal properties of several
57 medicinal plants more than 60 thousand years ago (Solecki 1975). The oldest record mentioning the usage
58 of medicinal plants for their activities comes from ancient Mesopotamia, around 2600 BC, which is not a
59 surprise given that they're a civilization known for keeping written records. The records describe around 1
60 thousand plants (and their compounds) along with their medicinal application, some of which are still in
61 use nowadays (Newman, Cragg, and Snader 2000). While human ancestors used plant products to relieve
62 pain or improve wound healing without any knowledge of their action mechanisms, recent developments
63 in molecular and cellular biology provide the opportunities to investigate the mechanism of action for these
64 natural products to use them more efficiently and assess their side effects and risks (Schenone et al. 2013).
65 The genus *Thymus* is a member of the *Lamiaceae* family and constitutes of 214 species spread across North
66 Africa, temperate Asia zone, and Europe, several members of this genus have been widely used in food,
67 cosmetics, perfumery, and pharmaceutical industries, they're also known to be widely used in traditional
68 medicine to treat digestive disorders, cough, diarrhea, headache, cold, bronchitis, renal stone, asthma, and
69 many other diseases, their essential oils contain several phenolic derivatives, terpenes, and esters, most of
70 which has been extensively researched (Salehi et al. 2019; Cornara et al. 2009; Alarcón et al. 2015;
71 Rowshan, Bahmanzadegan, and Saharkhiz 2013; X. Li et al. 2019). Several studies have also revealed that
72 extracts from several species of the *Thymus* genus possess antimicrobial, antioxidant, antitumor, anti-
73 inflammatory, analgesic, and other medically valuable properties (X. Li et al. 2019; Nabavi et al. 2015; Sarac
74 and Ugur 2008).

75 Previous *in vivo* and *in vitro* studies that investigated the extracts from *T. quinquecostatus*, *T.*
76 *vulgaris*, *T. carnosus*, *T. kotschyanus*, *T. mastichina*, and *T. citriodorus* also concluded their anticancer
77 potentials (Martins-Gomes et al. 2019; S. Wu et al. 2013; Martins-Gomes et al. 2018; Sun et al. 2005;
78 Heidari et al. 2018; Doosti, Ahmadi, and Fasihi-Ramandi 2018; Gordo et al. 2012; Abaza et al. 2015).
79 Further in-depth investigations into thymol (2-isopropyl-5-methylphenol, 36.0–55.0 % of essential oils
80 constituent, found in most of the *Thymus* species) had designated that it showed anticancer efficacy against
81 human liver cancer (Bel-7402), breast cancer (MCF-7), acute promyelocytic leukemia (HL-60), bladder
82 cancer (T24, SW780, and J82), immortalized urothelial (SV-HUC-1), colon adenocarcinoma (Caco-2),
83 ovarian cancer (SKOV-3) and colon cancer (HCT116 and LoVo) cell lines (QingHua, YinZhi, and FengXiang
84 2010; Seresht et al. 2019; Deb et al. 2011; Y. Li et al. 2017; Llana-Ruiz-Cabello et al. 2014; Zeng et al. 2020;

85 Elbe et al. 2020). Two other extracts, oleanolic acid and ursolic acid isolated from *T. mastichina* L. have
86 also been reported to exert improved synergistic anticancer activity on colon cancer (HCT-116) cell lines
87 (Gordo et al. 2012). Carvacrol, another monoterpene phenol found in the essential oils several *Thymus*
88 species are known to exert anticancer activity on human alveolar basal epithelial adenocarcinoma (A549),
89 hepatocellular carcinoma (HepG-2), breast cancer (MCF-7), and ovarian cancer (SKOV-3) cell lines
90 (Koparal and Zeytinoglu 2003; Elbe et al. 2020; Esmaeili-Mahani, Falahi, and Yaghoobi 2014; Patel, Shah,
91 and Bavadekar 2012; Yin et al. 2012). Rosmarinic acid has also been reported to possess the ability to inhibit
92 the proliferation of human colorectal adenocarcinoma (HT-29) cell lines with synergistic activity on some
93 other cancerous cell lines (Erenler et al. 2016). Similarly, apigenin, a dietary flavonoid found in the former
94 plants is known for its cell-cycle arrest and apoptosis induction activity in different tumor types such breast,
95 cervical, colon, lung, liver, prostate, pancreatic, and stomach (X. Li et al. 2019; Imran et al. 2020; Erenler et
96 al. 2016).

97 *Thymus cilicicus* Boiss. & Bal is a member of the *Thymus* genus, it is endemic to Turkey, the
98 Northern Aegean Islands, Lebanon, and Syria and is sold as a spice and herbal tea only in the Çamlı
99 (Chamli) village of Marmaris province in Mugla (Turkey), its locally known as lemon thyme, fish thyme,
100 and cheese thyme and commonly used for stomachache relief, it's also reported in the literature for its use
101 as a tranquilizer and for toothache relief. They can be consumed fresh at any time of the year or harvested
102 when they bloom and distilled in oil or dried for later use (Baser 2002; Gürdal and Kültür 2013; Everest and
103 Ozturk 2005). In a study conducted by Sarac and Ugur (2008), essential oils of *T. cilicicus* collected from
104 various regions of Mugla province were obtained by hydrodistillation and their antimicrobial activity
105 against some microorganisms was investigated, including multi-antibiotic-resistant bacteria, and gram-
106 positive bacterias, and yielded promising results.

107 In this study, the aerial shoots of *in vitro* propagated *T. cilicicus*. were isolated and dried, ethanol
108 extraction was performed on the dried leaves and the extract was analyzed for their wound healing property
109 on murine fibroblast (NIH-3T3), and their antiproliferative activity on NIH-3T3, human alveolar basal
110 epithelial adenocarcinoma (A549), human breast adenocarcinoma (MDA-MB-231), and human prostate
111 cancer (DU-145) cell lines. Computational analyses such as molecular docking was utilized to elucidate the
112 molecular mechanism underlying the potent antiproliferation activity on selected cell lines.

113 **2. Materials & Methods**

114 **2.1. Preparing the plant material**

115 *In vitro* cultures of *T. cilicicus* Boiss. & Bal. was obtained by following the optimum propagation
116 protocol reported by (Kaya et al. 2021). The aerial shoots of the plant were isolated and left to dry on top of
117 filter papers inside a dry air ventilating incubator at 30 °C for 24 hours, after 24 hours, the dry leaves were
118 weighed and transferred into a mortar. Liquid nitrogen was added until all the dry leaves were immersed
119 and they were milled by grinding until the liquid nitrogen evaporated and fine powders were obtained. The
120 dry powder was weighed and taken into a falcon into which 10 mL ethanol (99.9% pure laboratory-grade)
121 was added, the falcon was vortexed and placed into an ultrasonic bath for 1 hour. After 1 hour, the falcon
122 was vortexed again and the content was filtered into a clear beaker via a filter paper and left in a fume hood
123 overnight to allow the ethanol to evaporate. The dry extract was dissolved in Dimethyl sulfoxide (DMSO,
124 99.98% pure laboratory-grade) at a final concentration of 0.2 g/mL.

125 **2.2. Cell culturing and extract preparation**

126 A fresh batch of NIH-3T3 (RRID:CVCL_0594) cell line was thawed from a -86 °C stock and
127 seeded into a sterile T75 flask with 15 mL fresh high glucose DMEM (Sigma Dulbecco's Modified Eagle
128 Medium, supplemented with 10% fetal bovine serum, and 1% 10⁴ U/mL streptomycin, 10⁵ µg/mL
129 penicillin, and 25 µg/mL amphotericin B mix) and left to incubate in a humidified atmosphere with 5%
130 CO₂ at 37 °C until it reached 80% confluency (changing the medium every 24 hours). After reaching 80%
131 confluency, the cells were harvested and seeded into a sterile 96-well cell microplate at a concentration of
132 10⁴ cells per well per 200 µL. The same procedure was followed to prepare the cell microplates for the
133 A549 (RRID:CVCL_0023), MDA-MB-231 (RRID:CVCL_0062), and DU-145 (RRID:CVCL_0105) cell
134 lines. Each cell plate was incubated in a humidified atmosphere with 5% CO₂ at 37 °C for 24 hours.

135 Before applying the *T. cilicicus* extracts to the cell lines, the stock concentration of the extract (0.2
136 g/mL) was diluted 1/40-fold in the medium (DMEM) to obtain a working solution with a concentration of
137 2 mg/mL, further dilutions (with DMEM) were performed to obtain aliquots with concentrations ranging
138 between 1000 to 100 µg/mL. The same dilution ratio was used to dilute DMSO (1/40-fold in DMEM) which
139 was further diluted to obtain aliquots with concentrations ranging between 1000 to 100 µg/mL (normalized
140 control group). 1/40-fold dilution of the initial plant material and DMSO was performed to standardize the
141 toxic effects of DMSO on the cell lines (standardizing the toxicity of the solvents).

142 2.3. Colorimetric MTT assay

143 After incubating the 96-well cell microplates seeded with NIH-3T3, A549, MDA-MB-231, and
144 DU-145 cell lines for 24 hours, their mediums was discarded and 200 µL of each of the extract aliquots at
145 concentrations of 1000, 900, 800, 700, 600, 500, 400, and 300 µg/mL was added to 6 wells in each row (i.e.
146 sextuple replicas) and their DMSO controls were added to the remaining 6 wells of the same row at the
147 same concentration (i.e., each row contained 6 wells with extract aliquots at a particular concentration and
148 6 wells with the DMSO aliquots at the same concentration), each 96-well cell microplate was incubated in
149 a humidified atmosphere with 5% CO₂ at 37 °C for 24 hours. After 24 hours, the content of each plate was
150 discarded and the wells in each plate were rinsed with 100 µL D-PBS (Dulbecco's phosphate-buffered
151 saline, Pan Biotech, Turkey), and 200 µL fresh DMEM and 20 µL MTT reagent (3-(4,5-dimethylthiazol-
152 2-yl)-2,5-diphenyltetrazolium bromide prepared in D-PBS at a concentration of 5 mg/mL) was added to
153 each well. The plates were left in a humidified atmosphere with 5% CO₂ at 37 °C for 3 hours after which
154 their content was discarded (without disturbing the formazan crystals at the bottom of the wells) and 100
155 µL DMSO was added to each well of the cell plates and they were incubated at 37 °C in a shaking incubator
156 at 120 rpm for 20 minutes to dissolve the formazan crystals formed by MTT. After the incubation, the
157 absorbance of each microplate was immediately measured at 540 nm in a spectrophotometer.

158 To calculate the viability of the cell, the absorbance of the wells incubated with plant extract was
159 divided by the average absorbance of their corresponding DMSO control and converted into a percentage
160 by multiplying by 100 (cell viability percentage). The inhibition percentages were calculated via Eq. 1,
161 where $A_{540,X}$ is the absorbance of a well incubated with X concentration of the plant extract at 540 nm, and
162 $A_{540,\Delta CX}$ is the average absorbance of the control group at the same (X) concentration. A logarithmic plot
163 of the concentration against their respective inhibition percentages was plotted and the IC₅₀ (i.e., the
164 concentration required for 50% proliferation inhibition) was calculated from the equation of the line by
165 substituting 50 for y. SciPy (RRID:SCR_008058) was used to fit the data and their plots were generated
166 via Matplotlib (RRID:SCR_008624) and seaborn (RRID:SCR_018132) libraries in Python environment
167 (Hunter 2007; Waskom 2021; Virtanen et al. 2020).

$$168 \quad \text{Inhibition \%} = 100 - \text{Cell viability (\%)} \quad (\text{Eq. 1})$$

169
$$Cell\ viability\ (\%) = \left(\frac{A_{540,X}}{A_{540,\Delta CX}} \times 100 \right) \quad (Eq. 2)$$

170

171 2.4. Scratch wound assay

172 A portion of the freshly thawed NIH-3T3 cells was seeded into 6 sterile Petri dishes (2r=60 mm)
173 at a concentration of 1.25×10^5 cells per Petri dish and was incubated in a humidified atmosphere with 5%
174 CO₂ at 37 °C until they were completely coated with cells (confluency > 90%, ≈24 hours), after the
175 incubation period, their mediums were discarded, and scratch wound assay (artificial wound drawn across
176 the Petri dish) was performed on each of the 6 Petri dishes. The Petri dishes were rinsed in D-PBS and 2.5
177 mL of DMEM containing 100, 200, 300, and 400 µg/µL plant extract (1/40 diluted in DMEM as explained
178 above, doses selected were below the IC₅₀ obtained from the MTT assay in the previous step) was applied
179 to the first 4 Petri dishes, 2.5 mL 1/40-fold diluted DMSO was applied to the 5th Petri dish (normalized
180 solvent control) and 2.5 mL fresh DMEM was applied to 6th Petri dish (medium control). The area around
181 the artificial scratch wound was observed under a light microscope (and their snapshots taken) immediately
182 after adding the solutions and after 16 and 24 hours while incubating the Petri dishes in a humidified
183 atmosphere with 5% CO₂ at 37 °C.

184 2.5. Structure-based molecular docking analysis


185 To address the molecular mechanisms involved in the antiproliferation effect of *T. cilicicus* on the
186 A549 cell line, gene expression profiles derived from microarray results of A549 cells grown in *ex vivo*
187 (4D) and matrigel (3D) models reported by Mishra *et al.* (2014) was evaluated and the common genes
188 upregulated in both the models was collected (Mishra *et al.* 2014). The sequences for 9 common genes,
189 namely, *EIF5* (Eukaryotic translation initiation factor 5), *ABCC8* (ATP-binding cassette sub-family C
190 member 8), *GRIK2* (Glutamate receptor ionotropic, kainate 2), *COL4A6* (Collagen alpha-6 chain), *EPHA7*
191 (Ephrin type-A receptor 7), *KIAA1841* (uncharacterized protein), *GALNT5* (Polypeptide N-
192 acetylgalactosaminyltransferase 5), *DOCK4* (Dedicator of cytokinesis protein 4), and *MED31* (Mediator of
193 RNA polymerase II transcription subunit 31) were retrieved from UniProt and their 3D structures were
194 modeled via DeepMind's AlphaFold (The UniProt Consortium 2017; Jumper *et al.* 2021). A chemical
195 library containing 48 compounds present in the essential oils of *T. cilicicus* was prepared based on the GC
196 and GC/MS study reported by Tümen *et al.* (1994) (Tümen *et al.* 1994). Structure-based molecular docking
197 was performed with each of the 48 ligands against each of 9 protein structures via AutoDock Vina (v1.2.0)
198 using explicit hydrogens, search exhaustiveness of 64, Gasteiger empirical atomic partial charge model,
199 and continuum solvation models following the blind docking protocol (Trott and Olson 2010). Each protein-
200 ligand complex was evaluated based on their affinity scores (a scoring function based on binding affinity
201 implemented in AutoDock Vina) and the interaction profile of the top ligand for each protein was visualized
202 via Protein-Ligand Interaction Profiler (PLIP v2.2.2) (Salentin *et al.* 2015).

203 3. Result

204 3.1. Scratch wound assay

205 The dry weight of the extracts obtained was measured as 0.201 g, resulting in a yield of ≈30.78%.
206 Assessment of *T. cilicicus* wound healing properties was based on scratch wound assay, snapshots taken
207 after the initial application of the extract to the NIH-3T3 coated Petri dishes (t=0), and after 16 hours (t=16),
208 and 24 hours (t=24) of incubation is shown in Figure 1, the wound healing activity was evaluated based on


209 the migration rate of the NIH-3T3 cells over time towards the artificial wound (i.e. healing of the wound)
 210 at each concentration compared to the DMSO (solvent control) and DMEM (medium control) Petri dishes
 211 at the same time period. As shown in Figure 1, at any timestamp and across each concentration, the
 212 migration rate of the NIH-3T3 cells in the medium and DMSO control Petri dishes are higher than the
 213 migration rate in the Petri dishes treated with the plant extract, indicating a poor wound healing property
 214 (or a strong cytotoxicity). At the 24 hour timestamp, the artificial wound in the medium control is almost
 215 recovered, and the artificial wound in the DMSO control is significantly shrunken whereas the opposite is
 216 true for the Petri dishes treated with the plant extract.



217
 218 **Figure 1.** Assessment of *T. cilicucus* Boiss. & Bal. wound healing properties. Snapshots were taken
 219 immediately after introducing the artificial wound (t=0), after 16 hours (t=16), and after 24 hours (t=24),
 220 the extract concentration investigated were 100, 200, 300, and 400 µg/mL, DMSO Petri contains pure
 221 DMSO with DMEM but no plant extract (solvent control) whereas the Control Petri contains no DMSO or
 222 extract (medium control).

223 3.3. Colorimetric MTT assay

224 The dose-response plots (concentration against inhibition percentage) for each cell line investigated
 225 via MTT assay are shown in Figure 2, the results are also summarized in Table 1. By substituting $y=50$ in
 226 the line equations (shown on each plot in Figure 2), the IC_{50} for the NIH-3T3, A549, MDA-MB-231, and
 227 DU-145 cell lines was calculated as 556.58, 426.01, 1133.46, and 2219.09 µg/mL, respectively. As the
 228 NIH-3T3 cell line is a healthy (not a cancerous) cell line, the relative antiproliferative activity against A549,
 229 MDA-MB-231, and DU-145 cell lines were 0.77, 2.04, and 3.99 folds compared to the NIH-3T3 (calculated
 230 by dividing cancer cell's IC_{50} with NIH-3T3 cell line's IC_{50}). This results indicates *T. cilicucus* exerts
 231 selective antiproliferative activity on the A549 cell line. It's worth noting that the R^2 for the A549 dose-
 232 response plot was calculated as 0.928 whereas for MDA-MB-231 and DU-145 plots it was determined as
 233 0.443 and 0.773 respectively (Figure 2), indicating a higher bias in the calculated IC_{50} values for the latter
 234 2 cell lines.



235

236 **Figure 2.** Dose-response plots for NIH-3T3, A549, MDA-MB-231, and DU-145 cell lines. Concentration
 237 percentages were calculated based on Eq.1 after 24-hour incubation with *T. cilicicus* extracts.

238 **Table 1.** Results from MTT assay for NIH-3T3, A549, MDA-MB-231, and DU-145 cell lines 24 hours post-treatment
 239 with *T. cilicicus* ' extracts.

Concentration (µg/mL)	1000	900	800	700	600	500	400	300
NIH-3T3								
Cell viability (%)	11.19±0.90	15.36±0.22	22.06±2.25	38.20±5.09	42.55±2.13	46.10±6.00	84.4±12.83	92.0±27.25
Inhibition (%)	88.81	84.64	77.94	61.8	57.45	53.90	15.59	7.93
IC50*	556.58 µg/mL							
A549								
Cell viability (%)	17.37±0.63	25.37±0.88	25.94±0.63	26.94±1.14	39.19±5.23	51.44±5.06	54.6±8.46	57.65±6.29
Inhibition (%)	82.63	74.63	74.06	73.06	60.81	48.56	45.40	42.35
IC50*	426.01 µg/mL							
MDA-MD-231								
Cell viability (%)	18.32±5.70	43.69±12.60	134.91±4.03	138.19±0.44	110.35±2.55	109.95±0.65	114.56±12.2	100.66±6.02
Inhibition (%) ^{*L}	81.68	56.31	0	0	0	0	0	0
IC50*	<1133.46 µg/mL							
DU-145								
Cell viability (%)	70.91±7.55	72.42±1.31	76.60±7.82	79.90±12.05	140.29±40.5	115.45±20.8	116.36±45.2	100.76±2.15

Inhibition (%)*	29.09	27.58	23.40	20.10	0	0	0	0
IC ₅₀ [†]	2219.09 µg/mL							

* inhibitions percentages below 0% (i.e., no inhibition compared to their respective controls) were capped at 0%.

± indicates standard deviation.

[†] Calculated based on the equations derived in Figure 2 by solving for y=50.

L The pattern of narrow IC₅₀ range between 800-1000 µg/mL for MDA-MB-231 cell line persisted upon 3 independent repetitions of the experiment.

240

241 3.4. Structure-based molecular docking

242 The affinities calculated from docking the 9 upregulated proteins in A549 cell lines against the 48
243 components of *T. cilicicus* essential oils are summarized in Table 2. The raw results from the docking
244 experiment including the structure files are provided in the Supplementary Data 1 (S1).

245 **Table 2.** Results for structure-based molecular docking of 48 compounds found in *T. cilicicus* essential oils
246 against *EIF5*, *ABCC8*, *GRIK2*, *COL4A6*, *EPHA7*, *KIAA1841*, *GALNT5*, *DOCK4*, and *MED31* proteins.


Compound names	EIF5	ABCC8	MED31	EPHA7	GALNT5	COL4A6	KIAA1841	GRIK2	DOCK4
octanol	-3.70	-4.50	-3.80	-4.40	-5.10	-4.30	-3.90	-4.50	-4.50
camphor	-5.20	-6.00	-4.40	-5.00	-5.30	-5.00	-5.80	-5.40	-5.80
1-8-cineole	-4.90	-6.10	-4.50	-4.90	-5.30	-5.00	-5.50	-5.50	-6.00
eugenol	-5.10	-5.90	-4.70	-5.40	-6.80	-5.10	-5.60	-5.90	-5.90
bornyl acetate	-5.30	-6.80	-4.70	-5.30	-5.90	-5.80	-6.50	-5.90	-6.30
3-5-5-trimethyl-2-cyclohexenone	-4.90	-6.00	-4.70	-5.00	-6.10	-5.20	-5.30	-5.20	-6.10
linalool	-4.40	-5.50	-4.70	-4.50	-5.40	-4.90	-5.00	-5.00	-5.40
camphene	-5.00	-5.80	-4.50	-5.00	-5.60	-5.50	-5.30	-5.30	-5.90
α-pinene	-5.00	-6.00	-4.50	-5.20	-5.40	-5.10	-5.40	-5.70	-5.80
carvone	-5.50	-6.50	-4.90	-5.50	-6.80	-5.40	-5.90	-6.10	0.00
α-phellandrene	-5.40	-6.40	-4.90	-5.40	-6.60	-5.20	-5.40	-6.10	0.00
γ-terpinene	-5.00	-6.40	-4.70	-5.50	-6.80	-5.10	-5.40	-5.90	-5.90
α-terpinene	-5.20	-6.30	-5.10	-5.30	-6.80	-5.10	-5.30	-5.60	-6.00
p-cymene	-5.20	-6.20	-5.10	-5.30	-6.80	-5.20	-5.30	-6.30	-6.10
5-methyl-3-heptanone	-4.00	-4.60	-4.10	-4.30	-5.30	-4.10	-4.30	-5.20	-4.80
carvacrol	-5.40	-6.40	-5.40	-5.60	-7.00	-5.50	-5.90	-6.30	-6.20
myrtenol	-5.10	-5.80	-4.70	-4.90	-5.50	-5.50	-5.80	-5.20	-6.20
terpinen-4-ol	-5.20	-6.30	-5.00	-5.40	-5.70	-5.50	-5.50	-5.40	-6.10
terpinolene	-5.20	-6.70	-5.30	-5.40	-7.20	-5.30	-5.40	-6.00	-6.10
docosane	-4.40	-5.70	-4.40	-3.90	-5.30	-4.40	-4.50	-5.40	-4.80
p-cymen-8-ol	-5.40	-6.20	-5.00	-5.60	-6.90	-5.60	-5.80	-5.90	-6.40
β-pinene	-5.10	-6.00	-4.50	-4.90	-5.30	-5.10	-5.50	-5.60	-5.90
α-terpineol	-5.10	-6.10	-4.80	-5.40	-5.70	-5.40	-5.40	-5.70	-6.00
sabinene	-4.80	-6.30	-4.80	-5.20	-6.30	-5.20	-5.70	-5.90	-6.10
1-octen-3-ol	-3.70	-4.60	-4.10	-4.40	-5.20	-4.00	-4.00	-4.90	-4.60
limonene	-4.90	-6.30	-5.10	-5.30	-6.70	-5.20	-5.40	-6.00	-5.90

myrcene	-4.30	-5.60	-4.70	-5.20	-6.00	-4.20	-5.30	-4.90	-5.30
myrtenal	-5.30	-6.00	-4.70	-5.00	-5.50	-5.30	-5.90	-5.30	-6.10
pseudolimonene	-4.90	-6.30	-4.60	-5.00	-6.40	-5.10	-5.20	-6.10	-6.20
perillene	-4.60	-5.80	-4.80	-5.50	-5.90	-4.70	-5.30	-6.00	-5.60
tricyclene	-5.00	-5.90	-4.40	-5.00	-5.20	-5.20	-5.40	-5.40	-5.80
6-methyl-3-heptanol	-3.90	-4.80	-4.10	-4.30	-5.10	-4.30	-4.40	-4.80	-4.70
trans-pinocarveol	-5.20	-6.20	-4.80	-5.30	-5.40	-5.80	-6.10	-6.10	-6.10
spathulenol	-6.40	-7.60	-6.20	-6.30	-7.60	-6.40	-6.90	-6.80	-8.70
trans-campholenic aldehyde	-4.70	-5.90	-4.70	-4.80	-5.50	-5.40	-5.30	-5.30	-5.90
cis-verbenol	-5.20	-6.20	-5.00	-5.30	-5.40	-5.20	-5.80	-5.80	-5.90
β -bourbonene	-6.20	-7.80	-5.90	-6.20	-7.00	-6.20	-7.00	-6.30	-7.20
cis-carveol	-5.20	-6.10	-4.70	-5.20	-5.40	-5.30	-5.40	-5.40	-5.80
β -caryophyllene oxide	-6.20	-7.60	-6.30	-6.40	-7.50	-6.30	-7.00	-7.30	-7.40
z-3-hexenol	-3.90	-4.30	-3.80	-4.10	-4.40	-3.90	-3.70	-4.20	-4.40
β -caryophyllene	-6.70	-9.20	-6.30	-7.10	-7.70	-6.40	-6.80	-6.50	-7.70
germacrene d	-6.20	-7.50	-5.90	-6.30	-8.40	-6.40	-6.60	-7.00	-7.20
isoborneol	-5.00	-5.90	-4.40	-4.80	-5.40	-5.20	-5.70	-5.50	-5.80
cis-linalool oxide	-5.30	-5.80	-4.80	-5.40	-5.60	-5.30	-5.50	-5.70	-5.90
trans-linalool oxide	-5.10	-5.60	-4.60	-4.80	-5.30	-5.30	-5.50	-5.70	-5.70
γ -elemene	-5.70	-7.60	-5.60	-6.20	-7.20	-5.80	-6.10	-5.90	-7.00
trans-sabinene hydrate	-5.00	-6.20	-4.80	-5.70	-5.90	-5.40	-5.70	-6.10	-6.10
cis-sabinene hydrate	-4.90	-6.30	-4.60	-5.10	-6.30	-5.00	-5.40	-5.90	-6.20

*All values are in kcal/mol.

247

248 The ligands with the highest affinities for each of the proteins are further visualized in Figure 3.
 249 The highest affinities for each protein were *EIF5* with β -caryophyllene (-6.70 kcal/mol), *KIAA1841* with
 250 β -bourbonene and B-caryophyllene oxide (-7.00 kcal/mol), *GALNT5* with Germacrene D (-8.40 kcal/mol),
 251 *DOCK4* with Spathulenol (-8.70 kcal/mol), *MED31* with β -bourbonene and B-caryophyllene oxide (-6.30
 252 kcal/mol), *ABCC8* with β -caryophyllene (-9.20 kcal/mol), *COL4A6* with Spathulenol, β -caryophyllene, and
 253 Germacrene D (-6.40 kcal/mol), *GRIK2* with B-caryophyllene oxide (-7.30 kcal/mol), and *EPHA7* with β -
 254 caryophyllene (-7.10 kcal/mol). Both β -caryophyllene and β -caryophyllene oxide show strong affinities
 255 toward several proteins overexpressed in A549, highlighting their potential role in causing the selective
 256 inhibition of the A549 proliferation.



257

258 **Figure 3.** Interaction profiles of *T. cilicicus* essential oil extracts with the highest affinities towards *EIF5*,
 259 *ABCC8*, *GRIK2*, *COL4A6*, *EPHA7*, *KIAA1841*, *GALNT5*, *DOCK4*, and *MED31* proteins. Ligands are
 260 shown as green sticks, interacting residues of each protein is shown as blue sticks, hydrophobic interactions
 261 are shown in grey dashes, and hydrogen bonds are shown in continuous dark blue lines. All measurements
 262 are in Å.

263 4. Discussion

264 Cancer alone claims millions of lives annually despite the modern therapies and clinical
 265 interventions, the sophisticated molecular mechanism and the enormous variation in the disease's genetics
 266 and pathology from patient to patient is among the main reasons why a single cure approach is far from
 267 achievable, moreover, therapies that work efficiently in certain patients tend to stop working after some
 268 time as the development of drug resistance is common among cancer patients (Gottesman et al. 2016; WHO
 269 2021). Therefore, the research for novel anticancer therapeutics remains an intense area of research despite
 270 the availability of several chemotherapy agents since the first introduction of nitrogen mustards and
 271 antifolate drugs in chemotherapy regimens back in the 1940s (Chabner and Roberts 2005).

272 This study focused on the traditional method of investigating natural endemic plants used in folk
 273 medicine for their potent medicinal property, while several members of the thymus family are known for

274 their different medicinal properties, *T. cilicicus* has only been investigated for its antimicrobial activity
275 (Sarac and Ugur 2008). Initially, the ethanolic extract of the *T. cilicicus* was investigated for its wound
276 healing properties on the NIH-3T3 cell line which yielded poor results as it inhibited the migration of cells
277 even at the 100 µg/mL dose (Figure 1). This result indicated that *T. cilicicus* could hold a strong cytotoxicity
278 effect even at lower doses which was confirmed by colorimetric antiproliferation assays where *T. cilicicus*
279 extracts inhibited 50% of the NIH-3T3 cell proliferation at a concentration of 556.58 µg/mL (Figure 2 and
280 Table 1). Colorimetric MTT assay performed on A549, MDA-MB-231, and DU-145 cancer cells following
281 their exposure to *T. cilicicus* extract for 24 hours has shown some promising results, *T. cilicicus* extract
282 exhibited the weakest inhibitory activity on the DU-145 cell line with an IC₅₀ of 2219.09 µg/mL (4-folds
283 higher than that exhibited on the non-cancerous NIH-3T3 cell line), followed by MDA-MB-231 cell line
284 with an IC₅₀ of 1133.46 µg/mL (Table 2), however, the results from MDA-MB-231 cell line was
285 inconclusive as a pattern of no inhibition was observed at below 800 µg/mL even after 3 independent
286 repetitions of the same experiment, nevertheless, in 3 independent replicas of the experiment, the average
287 IC₅₀ was calculated to be ≈950 µg/mL, which is still 1.7-folds higher (but still significant) than that of the
288 non-cancerous NIH-3T3 cell line. The most promising result was achieved on the A549 for which the IC₅₀
289 was calculated as 426.01 µg/mL, lower than the IC₅₀ calculated on the non-cancerous NIH-3T3 cell line,
290 elucidating into a tumor cell-specific antiproliferative activity.

291 To further investigate the molecular mechanism involved in the selective inhibition of A549 cell
292 growth by *T. cilicicus* extracts, 9 proteins known for their upregulation in the A549 cell line (both in 3D
293 and 4D cell cultures) were modeled via AlphaFold from their respective sequences and molecular docking
294 was performed with them against 48 compounds found in the essential oils of *T. cilicicus* (Mishra et al.
295 2014; Tümen et al. 1994; Jumper et al. 2021). β-caryophyllene (which constitutes 1.37% of the essential
296 oils) achieved the highest affinity against *EIF5* (-6.7 kcal/mol), *ABCC8* (-9.2 kcal/mol), *COL4A6* (-6.4
297 kcal/mol), *EPHA7* (-7.1 kcal/mol), and *MED31* (-6.3 kcal/mol). β-caryophyllene oxide (which constitutes
298 2.53% of the essential oils) achieved the highest affinity against *GRIK2* (-7.3 kcal/mol), *KIAA1841* (-7.0
299 kcal/mol), and *MED31* (-6.3 kcal/mol). Germacrene D (which constitutes 1.08% of the essential oils)
300 exhibited a high affinity towards *COL4A6* (-6.4 kcal/mol) and *GALNT5* (-8.4 kcal/mol). Spathulenol (which
301 constitutes 0.29% of the essential oils) exhibited a high affinity towards *DOCK4* (-8.7 kcal/mol) and β-
302 bourbonene (which constitutes 0.32% of the essential oils) exhibited a high affinity towards *KIAA1841* (-
303 7.0 kcal/mol).

304 Downregulation of *MED31* has been reported to suppress the proliferation of osteosarcoma cells
305 and *in vitro* activation of *EPHA1* has been shown to promote angiogenesis and tumor growth in
306 hepatocellular carcinoma, the calculated affinity of β-caryophyllene on the former proteins indicate the
307 potential of a similar antiproliferation mechanism is involved in tumor suppression on the A549 cell line
308 (Buckens et al. 2020; Jiang et al. 2014). *GRIK2* has been used as an epigenetic target in gastric cancer for
309 its tumor suppressor role, this could hint into the role of β-caryophyllene oxide as a *GRIK2* agonist in the
310 A549 cell line to inhibit its proliferation (C.-S. Wu et al. 2010). *GALNT5* has been reported to be remarkably
311 upregulated in gastric carcinoma, and *in vivo* hamsters with knocked-down *GALNT5* were reported for low
312 proliferation, migration, and invasion of cholangiocarcinoma cells, Germacrene D affinity towards
313 *GALNT5* in the docking study could result in its downregulation in A549 cell line and synergistically exhibit
314 antiproliferative effect along with β-caryophyllene and β-caryophyllene oxide (Detarya et al. 2020).
315 *DOCK4* is known to mediate cancer cell migration through activation of *RAC1* (by interacting with
316 SH3YL1) in MDA-MB-231 breast cancer and spathulenol's affinity towards it provides some insights into
317 the potency of utilizing spathulenol to block cancer metastasis in *in vivo* models, moreover, *DOCK4*-
318 mediated *RAC1* activation is also involved in MDA-MB-231 breast cancer cell migration, which could
319 explain the uncanonical antiproliferative activity of *T. cilicicus* extracts in the MDA-MB-231 cell line only

320 at high concentration (as could be derived from the MDA-MB-231 dose-response plot in Figure 2) as the
321 amount of spathulenol in *T. cilicicus* constitutes only 0.29% of its essential oils (Kobayashi et al. 2014).

322 This study has investigated the medicinal use of endemic *T. cilicicus*, the antiproliferation assays
323 have revealed *T. cilicicus* extracts to possess selective antiproliferative activity on the A549 at significantly
324 low doses, these results were supported with computational analyses that revealed β -caryophyllene, β -
325 caryophyllene oxide, Germacrene D, and spathulenol (all of which are known to be present in *T. cilicicus*'
326 essential oils) to interact with several proteins known for their overexpression in A549 cell line. These
327 results align perfectly with previous studies on the essential oil components of *T. cilicicus*, β -caryophyllene,
328 and β -caryophyllene oxide has been reported for their anticancer and chemo-sensitizing properties (Fidy et
329 al. 2016; DI GIACOMO et al. 2017; Sultan et al. 2019) and several plants with high levels of Germacrene D
330 has been reported in the literature for their selective cytotoxicity on different cancer cell lines (Zarai et al.
331 2011; Casiglia et al. 2017; Al-Nemari et al. 2020). Spathulenol has also been reported to possess inhibitory
332 activity on B16-F10, HepG2, K562, and HL-60 cell lines and β -bourbonene has been reported to cause cell
333 cycle arrest at G₀/G₁ phase and induce apoptosis in PC-3M cell line (Bomfim et al. 2016; Wang et al. 2018).
334 This study serves as a precursor for further studies on *T. cilicicus* extracts for their anticancer efficiency
335 and efficacy in vivo and clinically as well as shed the light on its valuable importance to the
336 biopharmaceutical industry.

337

338 5. Supplementary Materials

339 S1: Structure files and raw results from molecular docking.

340 6. Competing interests

341 The authors declare no competing interests.

342 7. Acknowledgment

343 The authors are grateful to TUBITAK ULAKBIM, High Performance and Grid Computing Center
344 (TRUBA resources) for the computational resources they had provided for this study.

345 8. References

- 346 Abaza, Mohamed Salah I, Khaled Y Orabi, Ebtehal Al-Quattan, and Raja'a J Al-Attiyah. 2015. "Growth
347 Inhibitory and Chemo-Sensitization Effects of Naringenin, a Natural Flavanone Purified from
348 Thymus Vulgaris, on Human Breast and Colorectal Cancer." *Cancer Cell International* 15 (1): 46.
349 <https://doi.org/10.1186/s12935-015-0194-0>.
- 350 Alarcón, Rocío, Manuel Pardo-de-Santayana, Caroline Priestley, Ramón Morales, and Michael Heinrich.
351 2015. "Medicinal and Local Food Plants in the South of Alava (Basque Country, Spain)." *Journal of*
352 *Ethnopharmacology* 176: 207–24. <https://doi.org/10.1016/j.jep.2015.10.022>.
- 353 Al-Nemari, Rawan, Abdulrahman Al-Senaïdy, Abdelhabib Semlali, Mohammad Ismael, Ahmed Yacine
354 Badjah-Hadj-Ahmed, and Abir Ben Bacha. 2020. "GC-MS Profiling and Assessment of Antioxidant,
355 Antibacterial, and Anticancer Properties of Extracts of *Annona Squamosa* L. Leaves." *BMC*
356 *Complementary Medicine and Therapies* 20 (1): 296. <https://doi.org/10.1186/s12906-020-03029-9>.

- 357 Baser, K Hüsnü Can. 2002. "Aromatic Biodiversity among the Flowering Plant Taxa of Turkey." *Pure and*
358 *Applied Chemistry* 74 (4): 527–45. <https://doi.org/10.1351/pac200274040527>.
- 359 Bomfim, Larissa M, Leociley R A Menezes, Ana Carolina B C Rodrigues, Rosane B Dias, Clarissa A Gurgel
360 Rocha, Milena B P Soares, Albertino F S Neto, et al. 2016. "Antitumour Activity of the
361 Microencapsulation of Annona Vepretorum Essential Oil." *Basic & Clinical Pharmacology &*
362 *Toxicology* 118 (3): 208–13. <https://doi.org/https://doi.org/10.1111/bcpt.12488>.
- 363 Buckens, Oscar J, Btissame El Hassouni, Elisa Giovannetti, and Godefridus J Peters. 2020. "The Role of
364 Eph Receptors in Cancer and How to Target Them: Novel Approaches in Cancer Treatment." *Expert*
365 *Opinion on Investigational Drugs* 29 (6): 567–82. <https://doi.org/10.1080/13543784.2020.1762566>.
- 366 Casiglia, Simona, Maurizio Bruno, Massimo Bramucci, Luana Quassinti, Giulio Lupidi, Dennis Fiorini, and
367 Filippo Maggi. 2017. "Kundmannia Sicula (L.) DC: A Rich Source of Germacrene D." *Journal of*
368 *Essential Oil Research* 29 (6): 437–42. <https://doi.org/10.1080/10412905.2017.1338625>.
- 369 Chabner, Bruce A, and Thomas G Roberts. 2005. "Chemotherapy and the War on Cancer." *Nature*
370 *Reviews Cancer* 5 (1): 65–72. <https://doi.org/10.1038/nrc1529>.
- 371 Chatterjee, Nimrat, and Graham C Walker. 2017. "Mechanisms of DNA Damage, Repair, and
372 Mutagenesis." *Environmental and Molecular Mutagenesis* 58 (5): 235–63.
373 <https://doi.org/10.1002/em.22087>.
- 374 Cornara, L, A La Rocca, S Marsili, and M G Mariotti. 2009. "Traditional Uses of Plants in the Eastern
375 Riviera (Liguria, Italy)." *Journal of Ethnopharmacology* 125 (1): 16–30.
376 <https://doi.org/10.1016/j.jep.2009.06.021>.
- 377 Deb, Dipanwita Dutta, G Parimala, S Saravana Devi, and Tapan Chakraborty. 2011. "Effect of Thymol on
378 Peripheral Blood Mononuclear Cell PBMC and Acute Promyelotic Cancer Cell Line HL-60." *Chemico-*
379 *Biological Interactions* 193 (1): 97–106. <https://doi.org/10.1016/j.cbi.2011.05.009>.
- 380 Detarya, Marutpong, Kanlayanee Sawanyawisuth, Chaiwat Aphivatanasiri, Sriwipa Chuangchaiya,
381 Paksiree Saranaruk, Lukkana Sukprasert, Atit Silsirivanit, Norie Araki, Sopit Wongkham, and Chaisiri
382 Wongkham. 2020. "The O-GalNAcylating Enzyme GALNT5 Mediates Carcinogenesis and
383 Progression of Cholangiocarcinoma via Activation of AKT/ERK Signaling." *Glycobiology* 30 (5): 312–
384 24. <https://doi.org/10.1093/glycob/cwz098>.
- 385 Doosti, Mohammad-Hosseini, Kazem Ahmadi, and Mahdi Fasihi-Ramandi. 2018. "The Effect of Ethanolic
386 Extract of Thymus Kotschyianus on Cancer Cell Growth in Vitro and Depression-like Behavior in the
387 Mouse." *Journal of Traditional and Complementary Medicine* 8 (1): 89–94.
388 <https://doi.org/https://doi.org/10.1016/j.jtcme.2017.03.003>.
- 389 Elbe, Hulya, Gurkan Yigitturk, Turker Cavusoglu, Tuba Baygar, Melike Ozgul Onal, and Feral Ozturk. 2020.
390 "Comparison of Ultrastructural Changes and the Anticarcinogenic Effects of Thymol and Carvacrol
391 on Ovarian Cancer Cells: Which Is More Effective?" *Ultrastructural Pathology* 44 (2): 193–202.
392 <https://doi.org/10.1080/01913123.2020.1740366>.

- 393 Erenler, Ramazan, Ozkan Sen, Ilyas Yildiz, and Ali Aydın. 2016. "Antiproliferative Activities of Chemical
394 Constituents Isolated from *Thymus Praecox* Subsp. *Grossheimii* (Ronniger) Jalas." *Records of*
395 *Natural Products*, no. 6 November-December: 766–70.
- 396 Esmaeili-Mahani, Saeed, Farzaneh Falahi, and Mohammad Mehdi Yaghoobi. 2014. "Proapoptotic and
397 Antiproliferative Effects of *Thymus Caramanicus* on Human Breast Cancer Cell Line (MCF-7) and Its
398 Interaction with Anticancer Drug Vincristine." Edited by Mohd Roslan Sulaiman. *Evidence-Based*
399 *Complementary and Alternative Medicine* 2014: 893247. <https://doi.org/10.1155/2014/893247>.
- 400 Everest, Ayse, and Ersin Ozturk. 2005. "Focusing on the Ethnobotanical Uses of Plants in Mersin and
401 Adana Provinces (Turkey)." *Journal of Ethnobiology and Ethnomedicine* 1 (1): 6.
402 <https://doi.org/10.1186/1746-4269-1-6>.
- 403 Fidy, Klaudyna, Anna Fiedorowicz, Leon Strz̄adała, and Antoni Szumny. 2016. "β-Caryophyllene and β-
404 Caryophyllene Oxide-Natural Compounds of Anticancer and Analgesic Properties." *Cancer*
405 *Medicine* 5 (10): 3007–17. <https://doi.org/10.1002/cam4.816>.
- 406 GIACOMO, SILVIA DI, ANTONELLA DI SOTTO, GABRIELA MAZZANTI, and MICHAEL WINK. 2017.
407 "Chemosensitizing Properties of β-Caryophyllene and β-Caryophyllene Oxide in Combination with
408 Doxorubicin in Human Cancer Cells." *Anticancer Research* 37 (3): 1191 LP – 1196.
- 409 Gordo, Joana, Patrícia Máximo, Eurico Cabrita, Ana Lourenço, Abel Oliva, Joana Almeida, Mariana Filipe,
410 et al. 2012. "Thymus Mastichina: Chemical Constituents and Their Anti-Cancer Activity." *Natural*
411 *Product Communications* 7 (11): 1934578X1200701120.
412 <https://doi.org/10.1177/1934578X1200701120>.
- 413 Gottesman, Michael M, Orit Lavi, Matthew D Hall, and Jean-Pierre Gillet. 2016. "Toward a Better
414 Understanding of the Complexity of Cancer Drug Resistance." *Annual Review of Pharmacology and*
415 *Toxicology* 56: 85–102. <https://doi.org/10.1146/annurev-pharmtox-010715-103111>.
- 416 Gürdal, Bahar, and Sükran Kültür. 2013. "An Ethnobotanical Study of Medicinal Plants in Marmaris
417 (Muğla, Turkey)." *Journal of Ethnopharmacology* 146 (1): 113–26.
418 <https://doi.org/10.1016/j.jep.2012.12.012>.
- 419 Heidari, Zahra, Ali Salehzadeh, Seyed Ataollah Sadat Shandiz, and Sara Tajdoost. 2018. "Anti-Cancer and
420 Anti-Oxidant Properties of Ethanolic Leaf Extract of *Thymus Vulgaris* and Its Bio-Functionalized
421 Silver Nanoparticles." *3 Biotech* 8 (3): 177. <https://doi.org/10.1007/s13205-018-1199-x>.
- 422 Hunter, J D. 2007. "Matplotlib: A 2D Graphics Environment." *Computing in Science & Engineering* 9 (3):
423 90–95. <https://doi.org/10.1109/MCSE.2007.55>.
- 424 Imran, Muhammad, Tanweer Aslam Gondal, Muhammad Atif, Muhammad Shahbaz, Tahira Batool
425 Qaisarani, Muhammad Hanif Mughal, Bahare Salehi, Miquel Martorell, and Javad Sharifi-Rad. 2020.
426 "Apigenin as an Anticancer Agent." *Phytotherapy Research* 34 (8): 1812–28.
427 <https://doi.org/https://doi.org/10.1002/ptr.6647>.
- 428 Jiang, Chaoyin, Hua Chen, Lei Shao, and Qiaojie Wang. 2014. "MicroRNA-1 Functions as a Potential
429 Tumor Suppressor in Osteosarcoma by Targeting Med1 and Med31." *Oncol Rep* 32 (3): 1249–56.
430 <https://doi.org/10.3892/or.2014.3274>.

- 431 Jumper, John, Richard Evans, Alexander Pritzel, Tim Green, Michael Figurnov, Olaf Ronneberger, Kathryn
432 Tunyasuvunakool, et al. 2021. "Highly Accurate Protein Structure Prediction with AlphaFold."
433 *Nature* 596 (7873): 583–89. <https://doi.org/10.1038/s41586-021-03819-2>.
- 434 Kaya, Ergun, Mehmet Ali Balci, Omer Akguller, Selin Galatali, Sevil Yeniocak, Taner Mercan, Sevinc
435 Guldag, et al. 2021. "Development of an Optimum Proliferation Medium via the Graph Kernel
436 Statistical Analysis Method for Genetically Stable in Vitro Propagation of Endemic Thymus Cilicicus
437 (Turkey)." *Acta Botanica Croatica* 80 (2). <https://doi.org/10.37427/botcro-2021-024>.
- 438 Kobayashi, Masakazu, Kohei Harada, Manabu Negishi, and Hironori Katoh. 2014. "Dock4 Forms a
439 Complex with SH3YL1 and Regulates Cancer Cell Migration." *Cellular Signalling* 26 (5): 1082–88.
440 <https://doi.org/https://doi.org/10.1016/j.cellsig.2014.01.027>.
- 441 Koparal, A Tansu, and Melih Zeytinoglu. 2003. "Effects of Carvacrol on a Human Non-Small Cell Lung
442 Cancer (NSCLC) Cell Line, A549." *Cytotechnology* 43 (1–3): 149–54.
443 <https://doi.org/10.1023/b:cyto.0000039917.60348.45>.
- 444 Li, Xiao, Ting He, Xiuhuan Wang, Meng Shen, Xin Yan, Shusheng Fan, Le Wang, et al. 2019. "Traditional
445 Uses, Chemical Constituents and Biological Activities of Plants from the Genus Thymus." *Chemistry
446 & Biodiversity* 16 (9): e1900254. <https://doi.org/10.1002/cbdv.201900254>.
- 447 Li, Yi, Jia-ming Wen, Chuan-jun Du, Su-min Hu, Jia-xi Chen, Shi-geng Zhang, Nan Zhang, et al. 2017.
448 "Thymol Inhibits Bladder Cancer Cell Proliferation via Inducing Cell Cycle Arrest and Apoptosis."
449 *Biochemical and Biophysical Research Communications* 491 (2): 530–36.
450 <https://doi.org/10.1016/j.bbrc.2017.04.009>.
- 451 Llana-Ruiz-Cabello, María, Daniel Gutiérrez-Praena, Silvia Pichardo, F Javier Moreno, José María
452 Bermúdez, Susana Aucejo, and Ana María Cameán. 2014. "Cytotoxicity and Morphological Effects
453 Induced by Carvacrol and Thymol on the Human Cell Line Caco-2." *Food and Chemical Toxicology*
454 64: 281–90. <https://doi.org/10.1016/j.fct.2013.12.005>.
- 455 Lodish, Harvey F, Arnold Berk, Chris Kaiser, Monty Krieger, Matthew P Scott, Anthony Bretscher, Hidde L
456 Ploegh, and Paul T Matsudaira. 2008. *Molecular Cell Biology*. 5th ed. W.H. Freeman.
- 457 Martins-Gomes, Carlos, Eliana B Souto, Fernanda Cosme, Fernando M Nunes, and Amélia M Silva. 2019.
458 "Thymus Carnosus Extracts Induce Anti-Proliferative Activity in Caco-2 Cells through Mechanisms
459 That Involve Cell Cycle Arrest and Apoptosis." *Journal of Functional Foods* 54: 128–35.
460 <https://doi.org/10.1016/j.jff.2019.01.010>.
- 461 Martins-Gomes, Carlos, Meriem Taghouti, Judith Schäfer, Mirko Bunzel, Amélia M Silva, and Fernando M
462 Nunes. 2018. "Chemical Characterization and Bioactive Properties of Decoctions and
463 Hydroethanolic Extracts of Thymus Carnosus Boiss." *Journal of Functional Foods* 43: 154–64.
464 <https://doi.org/https://doi.org/10.1016/j.jff.2018.02.012>.
- 465 Mishra, Dhruva K, Chad J Creighton, Yiqun Zhang, Don L Gibbons, Jonathan M Kurie, and Min P Kim.
466 2014. "Gene Expression Profile of A549 Cells from Tissue of 4D Model Predicts Poor Prognosis in
467 Lung Cancer Patients." *International Journal of Cancer* 134 (4): 789–98.
468 <https://doi.org/10.1002/ijc.28428>.

- 469 Nabavi, Seyed Mohammad, Anna Marchese, Morteza Izadi, Valeria Curti, Maria Daglia, and Seyed Fazel
470 Nabavi. 2015. "Plants Belonging to the Genus Thymus as Antibacterial Agents: From Farm to
471 Pharmacy." *Food Chemistry* 173: 339–47. <https://doi.org/10.1016/j.foodchem.2014.10.042>.
- 472 Newman, D J, G M Cragg, and K M Snader. 2000. "The Influence of Natural Products upon Drug
473 Discovery." *Natural Product Reports* 17 (3): 215–34. <https://doi.org/10.1039/a902202c>.
- 474 Patel, Bhushankumar, Vichiksha R Shah, and Supriya A Bavadekar. 2012. "Anti-Proliferative Effects of
475 Carvacrol on Human Prostate Cancer Cell Line, LNCaP." *The FASEB Journal* 26 (S1): 1037.5-1037.5.
476 https://doi.org/https://doi.org/10.1096/fasebj.26.1_supplement.1037.5.
- 477 QingHua, Yin, Zhuang YinZhi, and Yan FengXiang. 2010. "Antitumor efficacy of thymol." *Progress in
478 Modern Biomedicine* 10 (11): 2073–75.
- 479 Rowshan, Vahid, Atefeh Bahmanzadegan, and Mohammad Jamal Saharkhiz. 2013. "Influence of Storage
480 Conditions on the Essential Oil Composition of Thymus Daenensis Celak." *Industrial Crops and
481 Products* 49: 97–101. <https://doi.org/10.1016/j.indcrop.2013.04.029>.
- 482 Salehi, Bahare, Mohammad Sanad Abu-Darwish, Amer Hussein Tarawneh, Celia Cabral, Anastasiya V
483 Gadetskaya, Ligia Salgueiro, Tahereh Hosseinabadi, et al. 2019. "Thymus Spp. Plants - Food
484 Applications and Phytopharmacy Properties." *Trends in Food Science & Technology* 85: 287–306.
485 <https://doi.org/10.1016/j.tifs.2019.01.020>.
- 486 Salentin, Sebastian, Sven Schreiber, V Joachim Haupt, Melissa F Adasme, and Michael Schroeder. 2015.
487 "PLIP: Fully Automated Protein–Ligand Interaction Profiler." *Nucleic Acids Research* 43 (W1):
488 W443–47. <https://doi.org/10.1093/nar/gkv315>.
- 489 Sarac, Nurdan, and Aysel Ugur. 2008. "Antimicrobial Activities of the Essential Oils of Origanum Onites
490 L., Origanum Vulgare L. Subspecies Hirtum (Link) Ietswaart, Satureja Thymbra L., and Thymus
491 Cilicicus Boiss. & Bal. Growing Wild in Turkey." *Journal of Medicinal Food* 11 (3): 568–73.
492 <https://doi.org/10.1089/jmf.2007.0520>.
- 493 Schenone, Monica, Vlado Dančik, Bridget K Wagner, and Paul A Clemons. 2013. "Target Identification
494 and Mechanism of Action in Chemical Biology and Drug Discovery." *Nature Chemical Biology* 9 (4):
495 232–40. <https://doi.org/10.1038/nchembio.1199>.
- 496 Seresht, Hasan Rezaei, Bushra Jabbar Albadry, Aseel Kamil Mohammed Al-mosawi, Omid Gholami, and
497 Hamid Cheshomi. 2019. "The Cytotoxic Effects of Thymol as the Major Component of
498 Trachyspermum Ammi on Breast Cancer (MCF-7) Cells." *Pharmaceutical Chemistry Journal* 53 (2):
499 101–7. <https://doi.org/10.1007/s11094-019-01961-w>.
- 500 Solecki, Ralph S. 1975. "Shanidar IV, a Neanderthal Flower Burial in Northern Iraq." *Science* 190 (4217):
501 880 LP – 881. <https://doi.org/10.1126/science.190.4217.880>.
- 502 Sudhakar, Akulapalli. 2009. "History of Cancer, Ancient and Modern Treatment Methods." *Journal of
503 Cancer Science & Therapy* 01 (02): i–iv. <https://doi.org/10.4172/1948-5956.100000e2>.
- 504 Sultan, Nahla, Azza I Othman, Mohamed A El-Missiry, Aly Fahmy Mohamed, and Sameh M Shabana.
505 2019. "Assessment of the Anticancer Activity of Caryophyllene Oxide against Breast Cancer Cell

- 506 Line and Related Genetic Alterations: In Vitro Study.” *Journal of Environmental Sciences. Mansoura*
507 *University* 48 (2): 87–94. <https://doi.org/10.21608/joese.2019.158392>.
- 508 Sun, Zhen-Xiao, Ying-Hui Zhang, Shuang Cheng, Qing-Wen Ma, Shan-Li Guo, and Jin-Bao Zhang. 2005.
509 “Anti-tumor effect of ethanol extracts from *Thymus quinquecostatus* Celak on human leukemia cell
510 line.” *Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine* 3 (5): 382–85.
511 <https://doi.org/10.3736/jcim20050513>.
- 512 The UniProt Consortium. 2017. “UniProt: The Universal Protein Knowledgebase.” *Nucleic Acids Research*
513 45 (D1): D158–69. <https://doi.org/10.1093/nar/gkw1099>.
- 514 Trott, Oleg, and Arthur J Olson. 2010. “AutoDock Vina: Improving the Speed and Accuracy of Docking
515 with a New Scoring Function, Efficient Optimization, and Multithreading.” *Journal of*
516 *Computational Chemistry* 31 (2): 455–61. <https://doi.org/10.1002/jcc.21334>.
- 517 Tümen, G, M Koyuncu, N Kirimer, and K H C Baser. 1994. “Composition of the Essential Oil of *Thymus*
518 *Cilicicus* Boiss. & Bal.” *Journal of Essential Oil Research* 6 (1): 97–98.
519 <https://doi.org/10.1080/10412905.1994.9698336>.
- 520 Virtanen, Pauli, Ralf Gommers, Travis E Oliphant, Matt Haberland, Tyler Reddy, David Cournapeau,
521 Evgeni Burovski, et al. 2020. “SciPy 1.0: Fundamental Algorithms for Scientific Computing in
522 Python.” *Nature Methods* 17: 261–72. <https://doi.org/10.1038/s41592-019-0686-2>.
- 523 Wang, Zhong, Feng Liu, Jian-Jun Yu, and Ji-Zhong Jin. 2018. “ β -Bourbonene Attenuates Proliferation and
524 Induces Apoptosis of Prostate Cancer Cells.” *Oncology Letters* 16 (4): 4519–25.
525 <https://doi.org/10.3892/ol.2018.9183>.
- 526 Waskom, Michael L. 2021. “Seaborn: Statistical Data Visualization.” *Journal of Open Source Software* 6
527 (60): 3021. <https://doi.org/10.21105/joss.03021>.
- 528 WHO. 2021. “Cancer.” WHO Statistics. 2021. [https://www.who.int/news-room/fact-](https://www.who.int/news-room/fact-sheets/detail/cancer)
529 [sheets/detail/cancer](https://www.who.int/news-room/fact-sheets/detail/cancer).
- 530 Wu, Chi-Sheng, Yen-Jung Lu, Hsin-Pai Li, Chuen Hsueh, Chang-Yi Lu, Yu-Wei Leu, Hao-Ping Liu, Kwang-
531 Huei Lin, Tim Hui-Ming Huang, and Yu-Sun Chang. 2010. “Glutamate Receptor, Ionotropic, Kainate
532 2 Silencing by DNA Hypermethylation Possesses Tumor Suppressor Function in Gastric Cancer.”
533 *International Journal of Cancer* 126 (11): 2542–52. <https://doi.org/10.1002/ijc.24958>.
- 534 Wu, Shuang, Feng-Xiang Wei, Hong-Zhi Li, Xiao-Guang Liu, Jian-Hua Zhang, and Jun-Xing Liu. 2013.
535 “Chemical composition of essential oil from *Thymus citriodorus* and its toxic effect on liver cancer
536 cells.” *Zhong yao cai = Zhongyaocai = Journal of Chinese medicinal materials* 36 (5): 756–59.
- 537 Yin, Qing-Hua, Feng-Xiang Yan, Xu-Yu Zu, You-Hua Wu, Xiao-Ping Wu, Ming-Chu Liao, Shu-Wen Deng,
538 Lei-Lan Yin, and Ying-Zhi Zhuang. 2012. “Anti-Proliferative and pro-Apoptotic Effect of Carvacrol on
539 Human Hepatocellular Carcinoma Cell Line HepG-2.” *Cytotechnology* 64 (1): 43–51.
540 <https://doi.org/10.1007/s10616-011-9389-y>.
- 541 Zarei, Zied, Adel Kadri, Ines Ben Chobba, Riadh Ben Mansour, Ahmed Bekir, Hafedh Mejdoub, and Néji
542 Gharsallah. 2011. “The In-Vitro Evaluation of Antibacterial, Antifungal and Cytotoxic Properties of

- 543 Marrubium Vulgare L. Essential Oil Grown in Tunisia." *Lipids in Health and Disease* 10 (1): 161.
544 <https://doi.org/10.1186/1476-511X-10-161>.
- 545 Zeng, Qiongyao, Yuncheng Che, Yu Zhang, Mei Chen, Qiang Guo, and Wenjing Zhang. 2020. "Thymol
546 Isolated from Thymus Vulgaris L. Inhibits Colorectal Cancer Cell Growth and Metastasis by
547 Suppressing the Wnt/ β -Catenin Pathway." *Drug Design, Development and Therapy* 14 (July): 2535–
548 47. <https://doi.org/10.2147/DDDT.S254218>.
- 549